

## Starpharma receives US\$3M milestone from AstraZeneca

**Melbourne, Australia; 11 February 2020:** Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received US\$3 million (A\$4.5 million) from AstraZeneca following the successful dosing of the first patient in the phase 1 clinical trial of AZD0466 (DEP<sup>®</sup> Bcl2/xL conjugate) in December.

As announced on 30 December 2019, the first patient dosed in the phase 1 trial triggered a US\$3 million milestone following commencement of AstraZeneca's first DEP<sup>®</sup> human clinical trial. The trial is being conducted at multiple sites in the US and will recruit patients with a range of cancers.

This milestone for AZD0466 falls under the company's multi-product license with AstraZeneca whereby Starpharma is eligible to receive development, launch and sales milestones of up to US\$124 million, plus tiered royalties on net sales for this initial product, and US\$93.3 million for each subsequent qualifying product.

AstraZeneca describes AZD0466 as having the potential to be a 'best-in-class' agent in this field with a broad opportunity in solid and haematological tumours (blood cancers) due to its ability to target both Bcl2 and Bcl/xL<sup>1</sup>.

The initial announcement made on 30 December 2019 is available via:

[www.starpharma.com](http://www.starpharma.com)

---

### About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel<sup>®</sup> portfolio and DEP<sup>®</sup> drug delivery with the Company developing several products internally and others via commercial partnerships.

**VivaGel<sup>®</sup>:** Starpharma's women's health product - VivaGel<sup>®</sup> BV is based on SPL7013, astodimer sodium, a proprietary dendrimer. VivaGel<sup>®</sup> BV for bacterial vaginosis (BV), is available for sale under the brand names Betafem<sup>®</sup> BV Gel (UK), Betadine BV<sup>™</sup> (Europe) and Fleurstat BVgel (Australia) and a new drug application has been submitted to the US FDA. Starpharma has licensed the sales and marketing of VivaGel<sup>®</sup> BV to ITF Pharma for the US; Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel<sup>®</sup> condom (an antiviral condom which includes VivaGel<sup>®</sup> in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel<sup>®</sup> condom has been launched in Japan under Okamoto's 003 brand, and in Australia and Canada under the LifeStyles Dual Protect<sup>®</sup> brand. The VivaGel<sup>®</sup> condom is approved in Europe.

**DEP<sup>®</sup> - Dendrimer Enhanced Product<sup>®</sup>:** Starpharma's DEP<sup>®</sup> drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP<sup>®</sup> programs, including improved efficacy, safety and survival. Starpharma has three internal DEP<sup>®</sup> products – DEP<sup>®</sup> docetaxel, DEP<sup>®</sup> cabazitaxel and DEP<sup>®</sup> irinotecan - in clinical development in patients with solid tumours. Starpharma's partnered DEP<sup>®</sup> programs include a multiproduct DEP<sup>®</sup> licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more. In June 2019 Starpharma signed a Development and Option agreement with AstraZeneca for a DEP<sup>®</sup> version of one of AstraZeneca's major marketed oncology medicines.

[Starpharma.com](http://Starpharma.com) | [Twitter](https://twitter.com/starpharma) | [LinkedIn](https://www.linkedin.com/company/starpharma)

---

### Media: WE

Rebecca Wilson  
Mob: +61 417 382 391  
[rwilson@we-worldwide.com](mailto:rwilson@we-worldwide.com)

Arthur Chan  
+61 2 9237 2805  
[arthurc@we-worldwide.com](mailto:arthurc@we-worldwide.com)

### Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704

[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)  
4-6 Southampton Crescent  
Abbotsford Vic 3067

### Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

---

<sup>1</sup> 3rd AstraZeneca-MedImmune-CRUK Cambridge Centre Symposium 2017 presentation



### **Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.